MuddyWater targets critical infrastructure in Israel and Egypt, relying on custom malware, improved tactics, and a predictable playbook.
Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results